ASCO 2026: Lilly’s Retevmo tied to dramatic outcomes in early‑stage RET fusion‑positive lung cancer on June 01, 2026 Adjuvant Therapy Benefit biomarker testing EFS gene eli lilly Non-Small Cell Lung Carcinoma Recurrence Response Evaluation Criteria in Solid Tumors Retevmo selpercatinib +
Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial on December 11, 2025 Adjuvant Therapy ER-positive giredestrant HER2-negative hormone receptor-positive Hormone Therapy Malignant neoplasm of breast oral SERD Recurrence Risk Roche (company) +
Roche's Oral SERD Giredestrant Delays Early Breast Cancer Recurrence in Late-Stage Trial on November 18, 2025 Adjuvant Therapy Disease-Free Survival ER-positive giredestrant HER2-negative Malignant neoplasm of breast oral SERD Phase 3 trial recurrence prevention Roche (company) +
Eli Lilly Highlights Verzenio’s Survival Benefit Amid Novartis Competition in Early Breast Cancer on August 27, 2025 Adjuvant Therapy Clinical Trials Eli Lilly HER2- HR+ Kisqali Malignant neoplasm of breast Novartis Overall Survival Verzenio +